Chargement en cours...
Primary trastuzumab resistance: new tricks for an old drug
Trastuzumab (Herceptin®) is the first FDA-approved therapeutic targeting a HER-family receptor tyrosine kinase (HER2/ErbB2/neu). Although trastuzumab is effective in the treatment of HER2-positive breast cancer, a substantial proportion of patients will not respond to trastuzumab-based regimens (pri...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3045786/ https://ncbi.nlm.nih.gov/pubmed/20973799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1749-6632.2010.05782.x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|